Journal article
Safety, clinical effectiveness and trough plasma concentrations of intravenous posaconazole in patients with haematological malignancies and/or undergoing allogeneic haematopoietic stem cell transplantation: Off-trial experience
W Jeong, P Haywood, N Shanmuganathan, J Lindsay, K Urbancic, MR Ananda-Rajah, SCA Chen, A Bajel, D Ritchie, A Grigg, JF Seymour, AY Peleg, DCM Kong, MA Slavin
Journal of Antimicrobial Chemotherapy | OXFORD UNIV PRESS | Published : 2016
DOI: 10.1093/JAC/DKW322
Abstract
Objectives: This study describes the safety, clinical effectiveness and trough plasma concentration (Cmin) of intravenous (iv) posaconazole, provided as part of Merck Sharp and Dohme Australia's Named Patient Programme (NPP) in non-clinical trial settings. Methods: A multicentre, retrospective study on the NPP use of iv posaconazole between July 2014 and March 2015 across seven Australian hospitals. Results: Seventy courses of iv posaconazolewere prescribed and evaluated in 61 patients receiving treatment for haematological malignancy. Sixty-one courses were prescribed for prophylaxis against invasive fungal disease (IFD), the majority of which (59) were initiated in patients with gastrointe..
View full abstractGrants
Funding Acknowledgements
M. A. S. and S. C. A. C. have received grants from Pfizer, Merck Sharp and Dohme (MSD) and Gilead Sciences. D. C. M. K. has sat on advisory boards for Pfizer and MSD, and received financial/travel support unrelated to the current work from Roche, Pfizer, MSD and Gilead Sciences. K. U. has sat on an advisory board for MSD. M. R. A.-R. has received honoraria from Schering Plough and Gilead, grants from MSD and participated in an advisory board for MSD. A. Y. P. has been on an advisory board for MSD unrelated to the current work. P. H. has sat on an advisory board for Amgen. All other authors: none to declare.